Pathological accumulation

Pathological accumulations refer to the abnormal buildup of substances—predominantly misfolded proteins, lipids, or mineral deposits—within or outside of cells, leading to progressive tissue damage and organ dysfunction [NIH, 2023]. In neurodegenerative disorders such as Alzheimer's and Parkinson's, these accumulations manifest as protein aggregates like amyloid-beta plaques, tau tangles, or alpha-synuclein inclusions that disrupt synaptic signaling and trigger apoptosis [PubMed: 32051515]. This phenomenon is also central to systemic diseases like transthyretin amyloidosis and atherosclerosis, where deposits impair cardiac or vascular integrity [StatPearls: Amyloidosis]. Therapeutic strategies focus on preventing the formation of these aggregates through molecular stabilizers or facilitating their removal using immunotherapy and enhanced autophagy pathways [Nature Reviews Drug Discovery, 2021]. However, targeting these accumulations is complex, as treatments must distinguish between toxic aggregates and functional protein monomers to avoid adverse effects like Amyloid-Related Imaging Abnormalities (ARIA) [FDA: Aducanumab Label]. Because 'Pathological accumulations' describes a broad class of disease manifestations rather than a single molecular target, it is typically categorized as a pathological endpoint rather than a specific receptor or enzyme.

Other names

Protein aggregationPathological depositsProteopathyInclusion bodiesAmyloidosisAggregopathyIntracellular inclusions

Monoclonal antibody-mediated immune clearance of aggregates, kinetic stabilization of precursor proteins to prevent misfolding, and RNA interference to reduce synthesis of amyloidogenic precursors.